Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study

Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study

Diğer sürümleri göster (1)

Background: New National Institute for Health and Care Excellence (NICE) guidance endorses the prescription of statins in larger population groups for the prevention of cardiovascular and cerebrovascular morbidity and mortality, especially in people with severe mental illness. However, the evidence...

Detaylı Bibliyografya
Asıl Yazarlar:	De Giorgi, R, De Crescenzo, F, Ostinelli, EG, Cowen, PJ, Harmer, CJ, Fazel, S, Cipriani, A
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2024

Benzer Materyaller

Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study
Yazar:: Andrea Cipriani, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study
Yazar:: Riccardo De Giorgi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Statins in depression: a repurposed medical treatment can provide novel insights in mental health
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Effects of various statins on depressive symptoms: is there enough evidence?
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Yazar:: Riccardo De Giorgi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Statins in depression: an evidence-based overview of mechanisms and clinical studies
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

The pharmacological bases for repurposing statins in depression: a review of mechanistic studies
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Yazar:: Riccardo De Giorgi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

The effects of statin monotherapy on depressive symptoms: a systematic review and meta-analysis
Yazar:: De Giorgi, R, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

The pharmacological bases for repurposing statins in depression: a review of mechanistic studies
Yazar:: Riccardo De Giorgi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

The serotonin 1A (5-HT1A) receptor as a pharmacological target in depression
Yazar:: Smith, ALW, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

An online experimental medicine trial on the effect of 28-day simvastatin administration on emotional processing, reward learning, working memory and salivary cortisol in healthy volunteers at risk for depression: OxSTEP protocol
Yazar:: Waters, S, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

An online evidence-based dictionary of common adverse events of antidepressants: a new tool to empower patients and clinicians in their shared decision-making process
Yazar:: Hong, JSW, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Statin-Associated Muscle Adverse Events : Update for clinicians
Yazar:: Maha A. Al-Mohaissen, ve diğerleri
Baskı/Yayın Bilgisi: (2016-11-01)

An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs
Yazar:: Chow, RTS, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study
Yazar:: De Crescenzo, F, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Statins in depression: a meta-analytic, epidemiological, and experimental medicine approach
Yazar:: De Giorgi, R
Baskı/Yayın Bilgisi: (2022)

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database
Yazar:: Bojing Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial
Yazar:: de Cates, AN, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Effect of statins on blood pressure: Analysis on adverse events released by FDA
Yazar:: Tao You, ve diğerleri
Baskı/Yayın Bilgisi: (2017-05-01)

The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action
Yazar:: Murphy, SE, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data
Yazar:: Furukawa, TA, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study
Yazar:: Molero, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research
Yazar:: Colwell, MJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Translating the promise of 5HT4 receptor agonists for the treatment of depression
Yazar:: Murphy, SE, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Adverse effects of statin therapy: real evidence
Yazar:: Marina G. Bubnova
Baskı/Yayın Bilgisi: (2019-03-01)

Factors associated with statin-related adverse muscular events in adult dyslipidemic outpatients
Yazar:: Paula Ferreira Castro, ve diğerleri
Baskı/Yayın Bilgisi: (2018-04-01)

Associations between statin use and negative affective bias during COVID-19: an observational, longitudinal UK study investigating depression vulnerability
Yazar:: Gillespie, AL, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug–drug interactions through the FDA adverse event reporting system
Yazar:: Sha Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004–2023
Yazar:: Ying Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Acute neural effects of fluoxetine on emotional regulation in depressed adolescents
Yazar:: Capitão, LP, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

A prospective stratified case-cohort study on statins and multiple adverse events in Japan.
Yazar:: Nobuhiro Ooba, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Development and validation of a meta-learner for combining statistical and machine learning prediction models in individuals with depression
Yazar:: Qiang Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory
Yazar:: Chen, R, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication
Yazar:: Ramli, FF, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
Yazar:: Yamin Shu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)